Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Bonate

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 2005
The distribution, metabolism, and elimination of clofarabine in ratsPeter L Bonate, Larry Arthaud, John Stuhler, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2023
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substratesYukio Otsuka, Srinivasu Poondru, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatmentVarsha Gandhi, William Plunkett, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primatesStacey L Berg, Peter L Bonate, Jed G Nuchtern, et al.
Journal of Clinical Pharmacology|November 19, 2024
In Vitro Evaluation of CYP-Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and NonsmokersMegumi Iwai, Jace Nielsen, Mayuko Miyagawa, et al.
Molecular Pharmacology|October 18, 2008
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicityRuoli Bai, Michael C Edler, Peter L Bonate, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 16, 2018
Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary talePeter L Bonate, Tianli Wang, Paul Passier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumorsScot Ebbinghaus, Eric Rubin, Evan Hersh, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 14, 2018
Correction to: Scientific white paper on concentration-QTc modelingChristine Garnett, Peter L Bonate, Qianyu Dang, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2010
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancerPeter L Bonate, Casey C Cunningham, Paul Gaynon, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 2005
The distribution, metabolism, and elimination of clofarabine in ratsPeter L Bonate, Larry Arthaud, John Stuhler, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 21, 2023
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substratesYukio Otsuka, Srinivasu Poondru, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2006
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatmentVarsha Gandhi, William Plunkett, Peter L Bonate, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primatesStacey L Berg, Peter L Bonate, Jed G Nuchtern, et al.
Journal of Clinical Pharmacology|November 19, 2024
In Vitro Evaluation of CYP-Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and NonsmokersMegumi Iwai, Jace Nielsen, Mayuko Miyagawa, et al.
Molecular Pharmacology|October 18, 2008
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicityRuoli Bai, Michael C Edler, Peter L Bonate, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 16, 2018
Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary talePeter L Bonate, Tianli Wang, Paul Passier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumorsScot Ebbinghaus, Eric Rubin, Evan Hersh, et al.
Journal of Pharmacokinetics and Pharmacodynamics|January 14, 2018
Correction to: Scientific white paper on concentration-QTc modelingChristine Garnett, Peter L Bonate, Qianyu Dang, et al.
Cancer Chemotherapy and Pharmacology|June 29, 2010
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancerPeter L Bonate, Casey C Cunningham, Paul Gaynon, et al.
Pageof 7